Galanthamine Fails to Reverse P-gp-Mediated Paclitaxel Resistance in Ovarian Cancer Cell Lines.

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Ovarian cancer exhibits poor prognosis due to chemoresistance, necessitating novel therapeutic strategies.
• Drug repurposing offers a promising approach to enhance chemotherapy efficacy and reduce toxicity.
• High-grade serous carcinoma is a major subtype of ovarian cancer with significant treatment challenges.

Purpose of the Study:

• To investigate the potential of galanthamine, an Alzheimer's disease medication, as a treatment for high-grade serous ovarian carcinoma.
• To evaluate galanthamine's individual and combined effects with paclitaxel on ovarian cancer cells.
• To determine if galanthamine can overcome paclitaxel resistance, potentially by interacting with P-glycoprotein.

Main Methods:

• Presto Blue assay for cell viability assessment.
• Immunocytochemical analysis to detect apoptosis and protein expression.
• Functional assays to evaluate P-glycoprotein drug efflux activity.

Main Results:

• Galanthamine exhibited no cytotoxic or synergistic effects on high-grade serous carcinoma cell lines.
• Galanthamine did not influence proteins related to cell viability, proliferation, or chemoresistance.
• Cellular assays confirmed that galanthamine does not impact P-glycoprotein's drug efflux function.

Conclusions:

• Galanthamine is not a viable option for reversing paclitaxel resistance in high-grade serous ovarian cancer.
• The study findings contradict previous suggestions of galanthamine's interaction with P-glycoprotein in this context.
• Further research into drug repurposing for ovarian cancer should consider alternative agents or mechanisms.